• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Development of a Discriminative and Biorelevant Dissolution Test Method for Atorvastatin/Fenofibrate Combination with Appliance of Derivative Spectrophotometry.采用导数分光光度法建立阿托伐他汀/非诺贝特组合制剂的鉴别性和生物相关性溶出度测试方法。
Turk J Pharm Sci. 2019 Mar;16(1):62-68. doi: 10.4274/tjps.77698. Epub 2018 Dec 31.
2
Development and Validation of Discriminating and Biorelevant Dissolution Test for Lornoxicam Tablets.氯诺昔康片鉴别及生物相关性溶出度试验的开发与验证
Indian J Pharm Sci. 2015 May-Jun;77(3):312-20. doi: 10.4103/0250-474x.159653.
3
Development and validation of a discriminative dissolution method for atorvastatin calcium tablets using in vivo data by LC and UV methods.应用 LC 和 UV 法从体内数据建立和验证阿托伐他汀钙片的区分性溶出方法。
AAPS PharmSciTech. 2014 Feb;15(1):189-97. doi: 10.1208/s12249-013-0053-z. Epub 2013 Nov 22.
4
Development and Validation of a Discriminative Dissolution Medium for a Poorly Soluble Nutraceutical Tetrahydrocurcumin.一种难溶性营养保健品四氢姜黄素的鉴别性溶出介质的开发与验证
Turk J Pharm Sci. 2021 Oct 28;18(5):565-573. doi: 10.4274/tjps.galenos.2021.91145.
5
Dissolution Profile of Mefenamic Acid Solid Dosage Forms in Two Compendial and Biorelevant (FaSSIF) Media.甲芬那酸固体剂型在两种药典及生物相关(FaSSIF)介质中的溶出曲线
Sci Pharm. 2016 Feb 14;84(1):181-90. doi: 10.3797/scipharm.ISP.2015.09. Print 2016 Jan-Mar.
6
Dissolution and spectrophotometric determination of astaxanthin in aqueous solutions.虾青素在水溶液中的溶解及分光光度法测定
Pharmazie. 2011 Aug;66(8):560-3.
7
Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.采用体外-体内模拟方法分析禁食状态下人用非诺贝特脂制剂的口服生物利用度增强。
Eur J Pharm Biopharm. 2013 Nov;85(3 Pt B):1274-84. doi: 10.1016/j.ejpb.2013.03.001. Epub 2013 Mar 14.
8
Development and validation of new discriminative dissolution method for carvedilol tablets.卡维地洛片新的鉴别溶出方法的开发与验证
Indian J Pharm Sci. 2011 Sep;73(5):527-36. doi: 10.4103/0250-474X.99000.
9
Development of a Suitable Dissolution Method for the Combined Tablet Formulation of Atorvastatin and Ezetimibe by RP-LC Method.采用反相液相色谱法开发阿托伐他汀和依折麦布复方片剂的合适溶出度测定方法。
Curr Drug Deliv. 2016;13(3):424-32. doi: 10.2174/1567201813666151201185206.
10
Investigation of the Dissolution Profile of Gliclazide Modified-Release Tablets Using Different Apparatuses and Dissolution Conditions.使用不同仪器和溶出条件研究格列齐特缓释片的溶出曲线
AAPS PharmSciTech. 2017 Jul;18(5):1785-1794. doi: 10.1208/s12249-016-0651-7. Epub 2016 Oct 31.

引用本文的文献

1
Romanian Wild-Growing -An Emerging Approach to a Potential Antimicrobial Engineering Carrier System Based on AuNPs: In Vitro Investigation and Evaluation.罗马尼亚野生植物——基于金纳米粒子的潜在抗菌工程载体系统的一种新兴方法:体外研究与评估
Plants (Basel). 2024 Mar 5;13(5):734. doi: 10.3390/plants13050734.
2
An Innovative Approach to a Potential Neuroprotective -Clinoptilolite Phyto-Nanocarrier: In Vitro Investigation and Evaluation.一种潜在神经保护沸石-植物纳米载体的创新方法:体外研究与评价。
Int J Mol Sci. 2024 Jan 30;25(3):1712. doi: 10.3390/ijms25031712.
3
Screening of Fenofibrate-Simvastatin Solid Dispersions in the Development of Fixed-Dose Formulations for the Treatment of Lipid Disorders.非诺贝特-辛伐他汀固体分散体在开发用于治疗脂质紊乱的固定剂量制剂中的筛选。
Pharmaceutics. 2023 Feb 10;15(2):603. doi: 10.3390/pharmaceutics15020603.
4
Enhancing Atorvastatin In Vivo Oral Bioavailability in the Presence of Inflammatory Bowel Disease and Irritable Bowel Syndrome Using Supercritical Fluid Technology Guided by wbPBPK Modeling in Rat and Human.利用超临界流体技术并结合大鼠和人体的 wbPBPK 模型指导,增强炎症性肠病和肠易激综合征大鼠和人体中阿托伐他汀的口服生物利用度。
AAPS PharmSciTech. 2022 May 18;23(5):148. doi: 10.1208/s12249-022-02302-z.

本文引用的文献

1
Development and Validation of Discriminating and Biorelevant Dissolution Test for Lornoxicam Tablets.氯诺昔康片鉴别及生物相关性溶出度试验的开发与验证
Indian J Pharm Sci. 2015 May-Jun;77(3):312-20. doi: 10.4103/0250-474x.159653.
2
Development and validation of a dissolution test for meloxicam and pridinol mesylate from combined tablet formulation.美洛昔康和甲磺酸普立地诺复方片剂溶出度试验的开发与验证
Indian J Pharm Sci. 2010 Mar;72(2):197-203. doi: 10.4103/0250-474X.65033.
3
Dissolution test for citalopram in tablets and comparison of in vitro dissolution profiles.西酞普兰片剂的溶出度试验及体外溶出曲线比较
Eur J Pharm Biopharm. 2007 Sep;67(2):524-30. doi: 10.1016/j.ejpb.2007.02.009. Epub 2007 Feb 20.
4
Development of a dissolution medium for nimodipine tablets based on bioavailability evaluation.基于生物利用度评价的尼莫地平片溶出介质的开发
Eur J Pharm Sci. 2004 Mar;21(4):487-91. doi: 10.1016/j.ejps.2003.11.009.
5
Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms.作为口服药物吸收预后工具的溶出度测试:速释剂型
Pharm Res. 1998 Jan;15(1):11-22. doi: 10.1023/a:1011984216775.

采用导数分光光度法建立阿托伐他汀/非诺贝特组合制剂的鉴别性和生物相关性溶出度测试方法。

Development of a Discriminative and Biorelevant Dissolution Test Method for Atorvastatin/Fenofibrate Combination with Appliance of Derivative Spectrophotometry.

作者信息

Anumolu Panukumar Durga, Gurrala Sunitha, Venkata Satya Subrahmanyam Chavali, Polisetty Santoshi Vani, Ravindran Anjana, Achanta Radhagayathri

机构信息

Osmania University, Gokaraju Rangaraju College of Pharmacy, Department of Pharmaceutical Analysis, Hyderabad, India.

出版信息

Turk J Pharm Sci. 2019 Mar;16(1):62-68. doi: 10.4274/tjps.77698. Epub 2018 Dec 31.

DOI:10.4274/tjps.77698
PMID:32454697
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7227977/
Abstract

OBJECTIVES

Nowadays, the market is flooded with combinations of drugs in various dosage forms, but there is a lack of official methods to quantify them. A single dissolution test method for the analysis of combined dosage form is preferred for simplification of quality control testing.

MATERIALS AND METHODS

If the developed dissolution medium mimics the biorelevant and discriminating dissolution procedure for drug products with limited drug aqueous solubility it is a useful tool for qualitative forecasting of the behavior of formulations.

RESULTS

Dissolution profiles were evaluated for atorvastatin and fenofibrate in capsules, using a paddle-type United States Pharmacopeia dissolution apparatus in 900 mL of medium at 50 rpm and 37±0.5°C. The best medium was 900 mL of 0.5% w/v sodium lauryl sulfate. The cumulative % dissolution was more than 85% within 45 min for marketed tablets. The proposed dissolution test conditions have discriminative power, dissimilarity factor (f) values are low (12-16%), and similarity (f) factor values are also low (45-48%). Hence the use of 0.5% w/v sodium lauryl sulfate solution is justified.

CONCLUSION

The dissolution method was validated (% relative standard deviation <2). To quantify both drugs simultaneously, a second derivative spectrophotometric method was established (λ 281 nm and 296 nm, respectively, for atorvastatin and fenofibrate) in acetate buffer, pH 2.8 solution.

摘要

目的

如今,市场上充斥着各种剂型的复方药物,但缺乏对其进行定量的官方方法。为简化质量控制检测,首选一种用于分析复方剂型的单一溶出度测试方法。

材料与方法

如果所开发的溶出介质模拟了具有有限药物水溶性的药品的生物相关且具有区分性的溶出程序,那么它就是预测制剂行为的有用工具。

结果

使用桨式美国药典溶出度测定仪,在900 mL介质中,转速为50 rpm,温度为37±0.5°C的条件下,对阿托伐他汀和非诺贝特胶囊的溶出曲线进行了评估。最佳介质是900 mL的0.5% w/v十二烷基硫酸钠。市售片剂在45分钟内累积溶出百分比超过85%。所提出的溶出度测试条件具有区分能力,差异因子(f)值较低(12 - 16%),相似性(f)因子值也较低(45 - 48%)。因此,使用0.5% w/v十二烷基硫酸钠溶液是合理的。

结论

溶出度方法经验证(相对标准偏差<2%)。为同时对两种药物进行定量,在pH 2.8的醋酸盐缓冲溶液中建立了二阶导数分光光度法(阿托伐他汀和非诺贝特分别在281 nm和296 nm波长处)。